Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLRP3 | Q96P20 | 7/20 | 0.47 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19519047 | 1.00 | NLRP3 (0.47) | NLRP3GSTO1MAPTPOLBRAF1 | |
| SCHEMBL23957304 | 0.87 | NLRP3 (0.50) | NLRP3GSTO1MAPT | |
| SCHEMBL29749221 | 0.86 | NLRP3 (0.58) | NLRP3GSTO1 | |
| SCHEMBL19519043 | 0.86 | NLRP3 (0.58) | NLRP3GSTO1 | |
| SCHEMBL23957307 | 0.85 | NLRP3 (0.62) | NLRP3GSTO1MAPT | |
| SCHEMBL19518817 | 0.83 | NLRP3 (0.55) | NLRP3GSTO1 | |
| SCHEMBL19518987 | 0.82 | NLRP3 (0.62) | NLRP3GSTO1 | |
| SCHEMBL23957241 | 0.82 | NLRP3 (0.49) | NLRP3GSTO1MAPTRAF1BRAF | |
| SCHEMBL23957306 | 0.82 | NLRP3 (0.48) | NLRP3GSTO1MAPT | |
| SCHEMBL23957237 | 0.82 | NLRP3 (0.48) | NLRP3GSTO1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NOVARTIS AG (CH) | 2023-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11597706-B2 | Compounds and compositions for treating conditions associated with NLRP activity | NLRP1, NLRP3, NOD1 | NLRP3 2/4885GSTO1 2939/4885MAPT 1325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.